Botox vs Dysport vs Xeomin: Which Neurotoxin Is Right for You?

Botox, Dysport, and Xeomin are all botulinum toxin type A — the same mechanism of action, the same target (the SNAP-25 protein at the neuromuscular junction), and the same clinical endpoint: temporary relaxation of the treated muscle. The differences lie in formulation, molecular weight, dosing units, diffusion radius, onset speed, and how the body handles the accessory proteins.

Understanding these differences helps you have a more informed conversation with your provider about which product is right for your anatomy and treatment goals.

The Mechanism: What All Three Products Do

All three are produced from Clostridium botulinum bacteria and contain botulinum toxin type A as the active molecule. When injected into a muscle, botulinum toxin A cleaves the SNAP-25 protein that nerve terminals use to release acetylcholine — the neurotransmitter that triggers muscle contraction. Without acetylcholine release, the muscle cannot contract.

The effect is temporary because the nerve terminal regenerates new SNAP-25 protein and establishes new neuromuscular junctions over 3–4 months, restoring normal function.

This mechanism is identical across all three products. The clinical differences come from what surrounds the toxin molecule.

The Key Differences

Molecular Formulation

Botox uses the full botulinum toxin complex including hemagglutinin and non-hemagglutinin proteins. These accessory proteins protect the toxin molecule and may influence how it spreads in tissue.

Dysport uses a smaller complex than Botox — the accessory proteins present are smaller in aggregate, resulting in a lower molecular weight overall. This contributes to its wider diffusion radius.

Xeomin strips the accessory proteins entirely, leaving only the purified 150kDa toxin molecule. This is intentional: the purified molecule is shelf-stable at room temperature before reconstitution (Botox and Dysport require refrigeration), and the absence of accessory proteins may reduce the risk of neutralizing antibody formation in patients who receive frequent high-dose treatments.

Dosing Units

The "units" for each product are not interchangeable — they are defined by individual manufacturer bioassays and have different potency relationships.

Approximate dose conversion:

• 1 unit Botox ≈ 2.5–3 units Dysport ≈ 1 unit Xeomin

In practice, this means:

• A standard forehead treatment of 20 units Botox corresponds to approximately 50–60 units Dysport
• Xeomin units are roughly equivalent to Botox units

An injector switching products must adjust the unit count accordingly — the same number of units of a different product is not the same dose.

Diffusion (Spread in Tissue)

This is the most clinically significant difference for treatment planning:

Botox has moderate, predictable diffusion. It stays relatively close to the injection point, making it well-suited for precision areas where you want targeted effect without spread to adjacent muscles — crow's feet, bunny lines, lip flip, and small corrective doses.

Dysport has the widest diffusion of the three. Its smaller molecular complex spreads more readily through tissue. For the forehead and glabellar complex (the large 11s muscles), this broad coverage can be an advantage — wider distribution with fewer injection points, and a smoother endpoint in the frontalis. In smaller or more anatomically crowded areas (around the eyes, perioral), this spread is a disadvantage: unintended diffusion to the levator palpebrae can cause temporary ptosis (drooping eyelid), and spread near the orbicularis can affect the upper lip.

Xeomin behaves similarly to Botox in terms of diffusion. The purified toxin molecule does not spread significantly differently from Botox in clinical practice.

Onset Speed

• Dysport: Typically the fastest onset — results often visible within 2–3 days
• Botox: Results typically visible by days 3–5, with full effect at 2 weeks
• Xeomin: Similar to Botox, with some providers noting a slightly slower initial onset for first-time users that evens out in subsequent sessions

The faster onset with Dysport is clinically useful when timing matters (events, photoshoots) but does not affect the final outcome.

Duration

All three products last approximately 3–4 months in most patients for standard cosmetic indications. Variation by individual matters more than product choice:

• Higher muscle mass and activity → shorter duration (strong masseters, active athletes)
• Higher metabolic rate → shorter duration
• Larger treatment doses → longer duration within the same session
• Consistent treatment history → some patients report longer duration over years of maintenance

There is no robust clinical evidence that one product systematically outlasts another when correctly dosed. Patient experience varies, and some individuals consistently prefer one product based on their personal duration history.

Which Product for Which Treatment Area?

Glabella (11s between the brows)

All three are appropriate. Dysport's broader spread covers the full corrugator/procerus complex effectively and is widely used here. Botox and Xeomin work equally well for injectors who prefer more targeted placement.

Forehead (horizontal lines)

Dysport is particularly well-suited given the large area of the frontalis muscle. Broader diffusion achieves good coverage. Botox is equally commonly used. Care must be taken with all three products to avoid over-relaxing the frontalis, which can cause brow ptosis — a heavy brow that sits lower than the patient's natural resting position.

Crow's feet (lateral orbicularis oculi)

Botox and Xeomin are preferred by many injectors for crow's feet. The contained diffusion is advantageous here — unintended spread toward the inferior oblique muscle (which controls eye movement) is undesirable. Dysport can be used but requires precise low-dose placement to limit spread.

Lip flip

Small doses of Botox (2–4 units) or Xeomin placed into the orbicularis oris along the upper lip cupid's bow cause the lip to relax and "flip" outward, creating the appearance of a fuller upper lip without adding volume. Dysport is not typically used for the lip flip because of its broader spread — diffusion to the deeper orbicularis or levator labii can cause temporary difficulty drinking through a straw, whistling, or enunciating certain sounds.

Masseter (jaw slimming/bruxism)

All three products are used for masseter injections. Botox is the most studied product for this indication. Dysport's broader diffusion is less of a concern in the masseter's large muscle bulk. Doses are significantly higher than cosmetic facial doses — typically 25–50 units Botox per side.

Hyperhidrosis (excessive sweating)

Botox (onabotulinumtoxinA) holds FDA approval for primary axillary hyperhidrosis at higher doses. All three products are used off-label for palmar, plantar, and other hyperhidrosis. The broader diffusion of Dysport can be useful for axillary coverage.

The Resistance Question: Does Xeomin Prevent Antibody Formation?

A subset of patients who receive frequent, high-dose botulinum toxin treatments develop neutralizing antibodies against the accessory proteins in Botox and Dysport. Over time, these antibodies can reduce the product's effectiveness — patients begin to need higher doses to achieve the same result, and eventually the product may stop working entirely in resistant individuals.

The theory behind Xeomin's "naked" toxin formulation is that without accessory proteins, there is no immune target for accessory protein antibodies. The neutralizing antibodies formed against Botox's complexing proteins would not interfere with Xeomin's purified toxin.

What the evidence shows:

• True clinical resistance is uncommon in cosmetic patients (who receive lower doses less frequently than therapeutic patients)
• There is theoretical support for reduced immunogenicity with Xeomin
• For patients who have undergone many years of high-dose Botox and notice diminishing effect, trialing Xeomin is a reasonable clinical decision
• For most cosmetic patients receiving 2–4 treatments per year, resistance is not a practical concern with any of the three products

Cost Considerations

Botox is typically priced by the unit, with per-unit costs ranging by geography and provider. Dysport, requiring more units for equivalent effect, is often priced at a lower per-unit cost — but the total session cost for comparable results is similar across products.

Xeomin is generally priced similarly to Botox on a per-unit basis. The lack of cold-chain storage requirements gives Xeomin a logistical cost advantage for providers, but this does not consistently translate to lower patient pricing.

When comparing quoted prices across providers, always confirm whether the quote is per-unit or per-area — per-area flat pricing obscures how much product is actually being used.

What Your Injector Thinks About Product Choice

Experienced injectors often have a preferred product for each treatment area based on their training and outcomes:

• Product familiarity matters significantly — an injector who has used Botox for 10 years knows exactly how it behaves in specific anatomy and achieves consistent results with it
• Switching is straightforward when the injector knows the dose-conversion ratios and has enough product volume experience
• Patient history informs choice — if you have had good results with one product, there is generally no reason to switch unless you want to explore the specific characteristics of another

For patients who have never received neurotoxin, the product choice matters less than the injector's expertise, the dose used, and the treatment plan for your anatomy.

Related guides: Botox aftercare — swelling and timeline · Botox forehead vs glabella treatment differences · How long after Botox can you exercise

AftercareGen creates clinic-branded post-treatment documents for Botox, Dysport, and Xeomin — including product-specific aftercare instructions and answers to the most common patient questions after neurotoxin treatment.